Supernus Pharmaceuticals Inc/ US8684591089 /
2024-06-11 10:00:00 PM | Chg. +0.0100 | Volume | Bid11:30:00 PM | Ask11:30:00 PM | High | Low |
---|---|---|---|---|---|---|
26.2000USD | +0.04% | 395,508 Turnover: 7.1 mill. |
14.4400Bid Size: 100 | 35.4000Ask Size: 100 | 26.3100 | 25.6400 |
GlobeNewswire
05-30
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
05-23
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epile...
GlobeNewswire
05-21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
05-12
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
05-09
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa St...
GlobeNewswire
05-02
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
04-24
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call o...
GlobeNewswire
04-24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
02-13
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Co...
GlobeNewswire
2023-11-02
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
GlobeNewswire
2023-10-25
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call o...
GlobeNewswire
2023-10-16
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journe...
GlobeNewswire
2023-10-10
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director